search
Back to results

A Study of OPC-262 in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
OPC-262
Sponsored by
Kyowa Kirin Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

20 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Type 2 diabetes patients with HbA1C above 6.5% and below 10% at both of the time of the 1st and the 2nd screening examinations and who have been undergoing diet and exercise therapies only for at least 8 weeks prior to the 1st screening examination
  2. Patients who are capable of giving informed consent
  3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)

Exclusion Criteria:

  1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus
  2. Patients with a medical history of diabetic coma
  3. Patients with poorly-controlled hypertension
  4. Patients with heart failure
  5. Patients with a complication of active hepatitis or hepatic cirrhosis
  6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy
  7. Patients with a history or complication of malignant tumor

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

OPC-262 5 mg

Arm Description

OPC-262 5 mg will be orally administered once daily fro 52 weeks.

Outcomes

Primary Outcome Measures

Changes in HbA1C from baseline to each visit (OC) and Week 52 (LOCF)
Clinical laboratory tests

Secondary Outcome Measures

Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF)

Full Information

First Posted
January 6, 2010
Last Updated
January 6, 2014
Sponsor
Kyowa Kirin Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01046318
Brief Title
A Study of OPC-262 in Patients With Type 2 Diabetes
Official Title
A Long-term Study of OPC-262 in Patients With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kyowa Kirin Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
OPC-262 5 mg
Arm Type
Experimental
Arm Description
OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Intervention Type
Drug
Intervention Name(s)
OPC-262
Intervention Description
OPC-262 5 mg will be orally administered once daily fro 52 weeks.
Primary Outcome Measure Information:
Title
Changes in HbA1C from baseline to each visit (OC) and Week 52 (LOCF)
Time Frame
each visit (OC) and Week 52 (LOCF)
Title
Clinical laboratory tests
Time Frame
every 4 weeks
Secondary Outcome Measure Information:
Title
Changes in fasting blood glucose (FBG) from baseline to each visit (OC) and Week 52 (LOCF)
Time Frame
each visit (OC) and Week 52 (LOCF)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes patients with HbA1C above 6.5% and below 10% at both of the time of the 1st and the 2nd screening examinations and who have been undergoing diet and exercise therapies only for at least 8 weeks prior to the 1st screening examination Patients who are capable of giving informed consent Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period) Exclusion Criteria: Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other specified drugs, mechanisms or diseases, and patients with gestational diabetes mellitus Patients with a medical history of diabetic coma Patients with poorly-controlled hypertension Patients with heart failure Patients with a complication of active hepatitis or hepatic cirrhosis Patients undergoing treatment of glomerular diseases other than diabetic nephropathy Patients with a history or complication of malignant tumor
Facility Information:
City
Chubu Region
Country
Japan
City
Kanto Region
Country
Japan
City
Tohoku Region
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

A Study of OPC-262 in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs